Jones David Scott 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Jan 26, 2024
Insider Transaction Report
Form 4
Jones David Scott
SVP & Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-01-24$3.26/sh+5,700$18,582→ 49,262 total - Sale
Common Stock
2024-01-24$25.01/sh−5,600$140,068→ 37,962 total - Sale
Common Stock
2024-01-25$25.00/sh−300$7,500→ 38,262 total - Sale
Common Stock
2024-01-25$25.00/sh−300$7,500→ 37,962 total - Sale
Common Stock
2024-01-24$25.01/sh−5,700$142,554→ 43,562 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-25−300→ 18,325 totalExercise: $12.90Exp: 2030-02-28→ Common Stock (300 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-24−5,700→ 85,455 totalExercise: $3.26Exp: 2033-01-05→ Common Stock (5,700 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-25−300→ 85,155 totalExercise: $3.26Exp: 2033-01-05→ Common Stock (300 underlying) - Exercise/Conversion
Common Stock
2024-01-25$12.90/sh+300$3,870→ 38,262 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-24−5,600→ 18,625 totalExercise: $12.90Exp: 2030-02-28→ Common Stock (5,600 underlying) - Exercise/Conversion
Common Stock
2024-01-24$12.90/sh+5,600$72,240→ 43,562 total - Exercise/Conversion
Common Stock
2024-01-25$3.26/sh+300$978→ 38,562 total
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.09. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.25. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
- [F4]The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.